Filing Details
- Accession Number:
- 0001179110-16-028505
- Form Type:
- 4
- Zero Holdings:
- No
- Publication Time:
- 2016-08-10 16:04:07
- Reporting Period:
- 2016-08-08
- Filing Date:
- 2016-08-10
- Accepted Time:
- 2016-08-10 16:04:07
- SEC Url:
- Form 4 Filing
Issuer
| Cik | Name | Symbol | Sector (SIC) | IRS No |
|---|---|---|---|---|
| 815094 | Abiomed Inc | ABMD | Surgical & Medical Instruments & Apparatus (3841) | 042743260 |
Insiders
| Cik | Name | Reported Address | Insider Title | Director | Officer | Large Shareholder | Other |
|---|---|---|---|---|---|---|---|
| 1456804 | G Michael Howley | C/O Abiomed, Inc. 22 Cherry Hill Drive Danvers MA 01923 | Vp, Global Sales & Marketing | No | Yes | No | No |
Reported Non-Derivative Transactions
| Sec. Name | Acquisiton - Disposition | Date | Amount | Price | Remaning Holdings | Equity Swap Involved | Form Type | Code | Nature of Ownership | Explanation |
|---|---|---|---|---|---|---|---|---|---|---|
| Common Stock, $.01 Par Value | Acquisiton | 2016-08-08 | 10,000 | $10.03 | 65,558 | No | 4 | M | Direct | |
| Common Stock, $.01 Par Value | Disposition | 2016-08-08 | 10,802 | $118.93 | 54,756 | No | 4 | S | Direct | |
| Common Stock, $.01 Par Value | Disposition | 2016-08-08 | 7,051 | $119.60 | 47,705 | No | 4 | S | Direct |
| Equity Swap Involved | Form Type | Code | Nature of Ownership | Explanation |
|---|---|---|---|---|
| No | 4 | M | Direct | |
| No | 4 | S | Direct | |
| No | 4 | S | Direct |
Reported Derivative Transactions
| Sec. Name | Sec. Type | Acquisiton - Disposition | Date | Amount | Price | Amount - 2 | Price - 2 |
|---|---|---|---|---|---|---|---|
| Common Stock | Stock Option (right to buy) | Disposition | 2016-08-08 | 10,000 | $0.00 | 10,000 | $10.03 |
| Remaning Holdings | Exercise Date | Expiration Date | Equity Swap Involved | Transaction Form Type | Transaction Code | Nature of Ownership |
|---|---|---|---|---|---|---|
| 0 | 2011-06-03 | 2020-06-03 | No | 4 | M | Direct |
Reported Derivative Holdings
| Sec. Name | Sec. Type | Price | Date | Expiration Date | Amount | Remaning Holdings | Nature of Ownership |
|---|---|---|---|---|---|---|---|
| Common Stock | Stock Option (Right to buy) | $22.44 | 2013-05-22 | 2022-05-22 | 0 | 25,000 | Direct |
| Common Stock | Stock Option (Right to Buy) | $23.15 | 2014-05-14 | 2023-05-14 | 0 | 25,000 | Direct |
| Common Stock | Stock Option (Right to Buy) | $21.55 | 2015-05-14 | 2024-05-14 | 0 | 25,000 | Direct |
| Common Stock | Stock Option (Right to Buy) | $66.25 | 2016-05-13 | 2025-05-13 | 0 | 5,000 | Direct |
| Common Stock | Stock Option (Right to Buy) | $99.62 | 2017-05-24 | 2026-05-24 | 0 | 8,000 | Direct |
| Expiration Date | Amount | Remaning Holdings | Nature of Ownership |
|---|---|---|---|
| 2022-05-22 | 0 | 25,000 | Direct |
| 2023-05-14 | 0 | 25,000 | Direct |
| 2024-05-14 | 0 | 25,000 | Direct |
| 2025-05-13 | 0 | 5,000 | Direct |
| 2026-05-24 | 0 | 8,000 | Direct |
Footnotes
- Grant to reporting person of option to buy the number of shares of common stock set forth on Table II, Column 7, under the Abiomed, Inc. 2008 Stock Incentive Plan.
- These options become exerciseable in annual 25% increments, commencing on the date shown forth in Table II, Column 6.
- These options become exercisable in annual 33-1/3% increments, commencing on the date shown in Table II, Column 6.
- Grant to reporting person of option to buy the number of shares of Common Stock set forth in Table II, Column 7, under the ABIOMED, Inc. 2015 Omnibus Incentive Plan.
- Sale of common stock pursuant to reporting owner's 10b5-1 plan.
- This price represents the weighted average sale price of multiple transactions on the reported date at prices that ranged between $118.3500 and $119.3300. Detailed information regarding the number of shares sold at each separate price will be provided upon request by the Commission staff, the Issuer, or a security holder of the Issuer
- This price represents the weighted average sale price of multiple transactions on the reported date at prices that ranged between $119.3600 and $120.0000. Detailed information regarding the number of shares sold at each separate price will be provided upon request by the Commission staff, the Issuer, or a security holder of the Issuer
Billionaire Hedge Funds
